The Landmark Series: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for Treatment of Gastric Cancer Metastatic to Peritoneum.
Sean P DineenJose M PimientoPublished in: Annals of surgical oncology (2021)
Gastric cancer (GC) is a common cancer worldwide, with patients developing isolated peritoneal metastases (PM) in approximately 30% of cases. In patients with PM, prognosis is quite poor, and long-term survival is almost zero. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has been demonstrated to be an effective treatment in many peritoneal malignancies, including appendiceal and ovarian cancers and in peritoneal mesothelioma. In this educational review, we summarize many of the seminal studies addressing the potential benefit of CRS/HIPEC for patients with gastric cancer and peritoneal metastases (GC/PM).
Keyphrases
- particulate matter
- air pollution
- minimally invasive
- end stage renal disease
- heavy metals
- coronary artery bypass
- squamous cell carcinoma
- chronic kidney disease
- polycyclic aromatic hydrocarbons
- ejection fraction
- small cell lung cancer
- locally advanced
- prognostic factors
- combination therapy
- replacement therapy
- peritoneal dialysis
- papillary thyroid
- climate change
- atrial fibrillation
- rectal cancer
- metastatic renal cell carcinoma
- liquid chromatography
- percutaneous coronary intervention
- chemotherapy induced